共找到 2 条结果
Low-field T2 mapping MRI can democratize neuropediatric imaging by improving accessibility and providing quantitative biomarkers of brain development. \textbf{Purpose:} To evaluate the feasibility of high-resolution T2 mapping using a single-shot fast spin-echo (SS-FSE) sequence at 0.55~T in a healthy control cohort. \textbf{Study Type:} Prospective single-center study. \textbf{Population:} In vivo: ten healthy adults (18--43~years, 5 females/5 males). In vitro: NIST Phantom. \textbf{Field strength/sequence:} Multi-echo ultra-fast spin-echo at 0.55~T and 1.5~T. \textbf{Assessment:} Feasibility was first assessed in vitro using the NIST Phantom, comparing T2 relaxation times to spectrometer references at 0.55~T. Acquisition and T2-fitting parameters optimized in vitro were applied in vivo. Repeatability was evaluated by atlas-based analysis of white matter (WM) and cortical grey matter (GM) regions. Coefficients of variation (CoV) were computed across runs, sessions, and subjects. \textbf{Statistical Tests:} Wilcoxon signed-rank test with Bonferroni correction ($α= 0.05/n_{ROI}$) assessed CoV differences. Pearson correlation coefficients quantified T2 associations. \textbf{Results:}
Aim: To determine the long-term efficacy of Katona therapy and early rehabilitation of infants with moderate-to-severe perinatal brain damage (PBD). Methods: Thirty-two participants were recruited (7-to-16 years) and divided into 3 groups: one Healthy group (n = 11), one group with PBD treated with Katona methodology from 2 months of corrected age, and with long-term follow-up (n = 12), and one group with PBD but without treatment in the first year of life due to late diagnosis of PBD (n = 9). Neuropediatric evaluations, motor evoked potentials (MEPs) and magnetic resonance images (MRI) were made. The PBD groups were matched by severity and topography of lesion. Results: The patients treated with Katona had better motor performance when compared to patients without early treatment (Gross Motor Function Classification System levels; 75% of Katona group were classified in levels I and II and 78% of patients without early treatment were classified in levels III and IV). Furthermore, independent k-means cluster analyses of MRI, MEPs, and neuropediatric evaluations data were performed. Katona and non-treated early groups were classified in the same MRI cluster which is the expected for